BPC-157 and TB-500 peptide claims: what the science actually shows

What did @buckeye_pmr actually say?

A physician on TikTok laid out a three-step protocol for treating osteoarthritis without joint replacement. Step one: inject alpha-2 macroglobulin (A2M) derived from your own blood to "get rid of the termites" he says are destroying cartilage. Step two: wear transdermal patches containing BPC-157, NAD, and GHK-Cu for six weeks to prep the joint. Step three: follow up with double-spin PRP, Wharton's jelly, or exosomes as a regenerative "fertilizer." He also claims NSAIDs "speed up" arthritis by inhibiting cartilage growth, and that each corticosteroid injection causes "up to 7% bone and mineral loss."

This is a complex, multi-part pitch. Some pieces have legitimate scientific backing. Others are speculative, overstated, or simply not supported by the evidence he implies exists. The framing as a definitive fix that "should last as long as you last" deserves real scrutiny.

Does the science back this up?

Partially, and with important caveats. The protease-driven model of osteoarthritis is real, but it is a significant oversimplification. A2M does show early promise as an intra-articular treatment, but the evidence base is thin. The peptide patch claims are the weakest link scientifically.

The protease hypothesis has support: matrix metalloproteinases (MMPs) and other degradative enzymes do contribute to cartilage breakdown in osteoarthritis (Goldring and Goldring, 2010, Arthritis Research and Therapy). A2M has been studied as a protease inhibitor in synovial fluid. Moser et al. (2018, Journal of Orthopaedic Research) found A2M reduced MMP activity in vitro, and small clinical series suggest symptom improvement, but there are no large randomized controlled trials confirming the "get rid of the cause" framing he uses.

BPC-157 has shown tendon and soft tissue healing effects in rodent models (Sikiric et al., 2018, Current Pharmaceutical Design), but there are zero published human clinical trials on intra-articular or transdermal BPC-157 for osteoarthritis. GHK-Cu has demonstrated some pro-collagen signaling in cell studies (Pickart et al., 2015, Journal of Aging Science), but again, transdermal delivery to a joint specifically has not been validated in clinical trials.

What did they get wrong (or right)?

The NSAID claim deserves a closer look. He says NSAIDs "inhibit cartilage growth" via COX-2 inhibition and therefore accelerate joint destruction. This is not a fringe idea. There is real evidence that COX-2 inhibition can impair chondrocyte function and some observational data linking long-term NSAID use to accelerated radiographic joint space narrowing (Helin-Salmivaara et al., 2006, Annals of the Rheumatic Diseases). Calling them definitively cartilage-destroying is an overstatement, but the concern is scientifically grounded.

The corticosteroid "7% bone and mineral loss per injection" claim is where things get shaky. Intra-articular corticosteroids are associated with local tissue effects and some systemic absorption, but the specific 7% per-injection figure appears to lack a clear published source. McAlindon et al. (2017, JAMA) did find accelerated cartilage volume loss with repeated intra-articular triamcinolone, which supports caution, but the precise quantification he cites is not traceable to peer-reviewed literature.

He correctly identifies that Wharton's jelly, exosomes, and PRP have overlapping mechanisms, though calling them interchangeable is an oversimplification that most regenerative medicine researchers would push back on.

What should you actually know?

The regenerative medicine space he is operating in is real medicine being actively researched, but it is not settled medicine. The A2M procedure is offered by a growing number of clinics, but it is not FDA-approved as a specific arthritis treatment, and out-of-pocket costs are substantial with no insurance coverage. Patients should ask for informed consent documentation that includes the current state of the evidence, not just a mechanistic pitch.

Transdermal peptide patches are the most speculative part of this protocol. Skin is an excellent barrier, and the evidence that BPC-157 or GHK-Cu penetrates to joint tissue via a topical patch at therapeutic concentrations does not exist in the published human literature. That does not mean the components have no biological activity, but it does mean the delivery claim is being carried by logic and cell-culture data, not clinical proof.

Anyone considering this approach should have a frank conversation with a board-certified orthopedic surgeon or rheumatologist alongside a regenerative medicine provider. The idea of preserving a joint rather than replacing it is a reasonable goal shared by mainstream medicine. The specific protocol described here goes well beyond what current evidence can confirm.

Bottom line

This creator is a physician presenting a mechanistically coherent but evidence-light protocol. The underlying biology is not invented. The extrapolation from that biology to a specific multi-step commercial protocol is where the gap between hypothesis and proof opens up. Patients with osteoarthritis deserve to know the difference.